Morus alba L. suppresses the development of atopic dermatitis induced by the house dust mite in NC/Nga mice
© Lim et al.; licensee BioMed Central Ltd. 2014
Received: 14 August 2013
Accepted: 16 April 2014
Published: 23 April 2014
Morus alba, a medicinal plant in Asia, has been used traditionally to treat diabetes mellitus and hypoglycemia. However, the effects of M. alba extract (MAE) on atopic dermatitis have not been verified scientifically. We investigated the effects of MAE on atopic dermatitis through in vitro and in vivo experiments.
We evaluated the effects of MAE on the production of nitric oxide (NO) and prostaglandin E2 (PGE2) in RAW 264.7, as well as thymus and activation-regulated chemokine (TARC/CCL17) in HaCaT cells. In an in vivo experiment, atopic dermatitis was induced by topical application of house dust mites for four weeks, and the protective effects of MAE were investigated by measuring the severity of the skin reaction on the back and ears, the plasma levels of immunoglobulin E (IgE) and histamine, and histopathological changes in the skin on the back and ears.
MAE suppressed the production of NO and PGE2 in RAW 264.7 cells, as well as TARC in HaCaT cells, in a dose-dependent manner. MAE treatment of NC/Nga mice reduced the severity of dermatitis and the plasma levels of IgE and histamine. MAE also reduced the histological manifestations of atopic dermatitis-like skin lesions such as erosion, hyperplasia of the epidermis and dermis, and inflammatory cell infiltration in the skin on the back and ears.
Our results suggest that MAE has potent inhibitory effects on atopic dermatitis-like lesion and may be a beneficial natural resource for the treatment of atopic dermatitis.
KeywordsAtopic dermatitis Keratinocyte Macrophage Morus alba NC/Nga mouse
Atopic dermatitis is a multifactorial disease that depends on a genetic predisposition to allergy, which is characterized by complex immune mechanisms in the development of allergic skin inflammation . Complex interrelationships between genetic, environmental, skin barrier, pharmacological, psychological and immunological factors contribute to the pathogenesis of atopic dermatitis, but its immunological basis is of considerable importance, and it has been studied extensively . Immunological analyses of atopic dermatitis have shown that the activation of mast cells and differentiated T-helper 2 (Th2) cells by various mediators have major roles in the development of dermatitis [3, 4]. Previous studies have shown that atopic dermatitis is associated with increased serum immunoglobulin (Ig) E levels, the Th2 chemokine level in the lesional skin, the serum eosinophil count, and the expression of proinflammatory enzymes such as nitric oxide (NO) and prostaglandin E2 (PGE2) [5, 6].
Morus alba L. (Moraceae) is a traditional medicinal herb used for the prevention and treatment of several diseases, such as jaundice, hematemesis, and pollakisuria [7, 8]. Phytochemical studies of M. alba have identified alkaloids, flavonoids, glycosides, terpenoids, steroids, volatile oils and tannins [9–11]. The biological activities of M. alba include antidiabetic, hypolipidemic, antihypertensive, antimicrobial, antioxidant, antiatherosclerotic, anticancer, neuroprotective, and antiulcer effects [12–16]. However, there was no study on the effects of M. alba on atopic dermatitis. Therefore, we investigated the effect of M. alba extract (MAE) on NO and PGE2 production in RAW 264.7 macrophages, and thymus and activation-regulated chemokine (TARC) production in HaCaT keratinocytes. We examined the effects of MAE on NC/Nga mice as a model of house dust mite-induced atopic dermatitis. We measured the skin severity score, histological changes in the skin, including mast cell infiltration, and the plasma IgE and histamine levels. The effect of MAE might be associated with the suppression of the inflammatory response in atopic dermatitis.
Reagents and materials
Dried M. alba (200 g) was extracted three times with 70% ethanol (2 L) by sonication for 60 min. The extract was filtered, evaporated to dryness, and freeze-dried (11.35 g). The yield was 5.68%. The M. alba used in this experiment was purchased from HMAX (Jecheon, Korea) in October 2008. The origin of the sample was confirmed taxonomically by Professor Je-Hyun Lee, Dongguk University, Gyeongju, Republic of Korea. A specimen (2008-ST12) has been deposited in the Basic Herbal Medicine Research Group, Korea Institute of Oriental Medicine.
Biostir-AD®, an ointment that contains house dust mite (Dermatophagoides farina) extract, was purchased from Biostir Inc. (Kobe, Japan), while 0.1% Tacrolimus (Protopic®; Astellas, Grand Island, NY, USA) was used as a the positive control.
The murine macrophage RAW 264.7 cells and human keratinocyte HaCaT cells were obtained from the American Type Culture Collection (Rockville, MD, USA). They were cultured in Dulbecco’s modified Eagle’s medium (Gibco Inc., Grand Island, NY, USA) supplemented with 5.5% (for Raw 264.7) or 10% (for HaCaT) heat-inactivated fetal bovine serum (Gibco Inc.), penicillin (100 U/mL), and streptomycin (100 μg/mL) in a 5% CO2 incubator at 37°C.
Cell viability was assessed with the CCK-8 assay (Cell Counting Kit-8, Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer’s instructions. RAW 264.7 cells (3 × 103 cells/well) and HaCaT cells (1 × 103 cells/well) were incubated in 96-well plates with various concentrations of the MAE for 24 h. CCK-8 reagent was added to each well and incubated for 4 h. The absorbance was measured at 450 nm with a Benchmark plus microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). The percentage of cell viability was calculated with the following formula: cell viability (%) = (mean absorbance in test wells/mean absorbance in control wells) × 100.
Measurement of nitrite and PGE2 production
RAW 264.7 cells were plated at a density of 2.5 × 105 cells/well on 48-well plates and incubated overnight. The cells were treated with lipopolysaccharide (LPS, 1 μg/mL) in the absence or presence of various concentrations of MAE. After incubation for 24 h, the supernatants were used to determine the levels of nitrite (Griess Reagent System, Promega Co., Madison, WI, USA) and PGE2 (PGE2 enzyme linked immunosorbent assay (ELISA) kit, Cayman Chemical Co., Ann Arbor, MI, USA).
Measurement of TARC production
HaCaT cells (1 × 106 cell/well) were cultured on six-well plates. After reaching a confluent state, the cells were washed and treated with MAE in 1 mL of serum-free medium containing tumor necrosis factor (TNF)-α and interferon (IFN)-γ (each 10 ng/mL; R&D Systems Inc., Minneapolis, MN, USA) for 24 h. The supernatants were harvested, and TARC production was quantified using an ELISA kit (R&D Systems Inc., Minneapolis, MN, USA).
Male NC/Nga mice (eight weeks old) were purchased from Central Laboratory Animal Inc. (Seoul, Korea). The animals were housed in an air-conditioned room and maintained at 24 ± 2°C and 55 ± 15% humidity. All experimental procedures were carried out in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals and were approved by Korea Institute of Oriental Medicine Institutional Animal Care and Use Committee (Approval number: #10-052).
Induction of atopic dermatitis in NC/Nga mice
Atopic dermatitis-like skin lesions were induced in 10-week-old male NC/Nga mice using Biostir-AD, as described by the manufacturer with some modifications . Briefly, the upper back was shaved, and 200 μL of 4% (w/v) sodium dodecyl sulfate (SDS) was applied to the shaved dorsal skin and both surfaces of each ear for barrier disruption. After 2 h, 50 mg of Biostir-AD was applied topically and twice per week for four weeks. The mice were allocated to four random groups (n = 7/group): normal control group (vehicle-treated mice; 70% ethanol/PBS (ratio 1:9), 200 μL/mouse), Biostir group (Biostir-AD plus vehicle-treated mice), Tacrolimus group (Biostir-AD plus Tacrolimus ointment-treated mice; 50 μg/mouse), and MAE group (Biostir-AD plus MAE-treated mice; 10 mg/mouse). The effective dose of MAE was determined according to preliminary study. We have used 10 mg/kg and 20 mg/kg of MAE as experimental doses in preliminary study. The procedure of preliminary study was same to present study. The skin severity significantly decreased in both 10 and 20 mg/kg of MAE compared with the animal with atopic dermatitis. However, the skin severity of 10 mg/kg more decreased than that of 20 mg/kg. MAE was dissolved 70% ethanol/PBS (ratio = 1:9) and applied every day for four weeks. The mice were sacrificed under anesthesia with pentobarbital (200 μg/mouse, i.p.) on the day of the experiment. During the autopsy, blood was collected from the posterior vena cava, and the back skin and each ear were excised for the histopathological analyses.
Evaluation of skin severity
The relative severity of dermatitis was assessed macroscopically according to the Eczema Area and Severity Index (EASI) scoring system: 0, no symptoms; 1, mild symptoms; 2, moderate symptoms; and 3, severe symptoms. The dermatitis score was defined as the sum of the scores for erythema/hemorrhage, edema, excoriation/erosion, and scaling/dryness . The range of dermatitis score is 0 to 12. The mice were also photographed once each week. The dermatitis scoring is conducted throughout blind test. Two veterinarian and three animal study experts participated in blind test.
After sacrifice, the back skin and one ear of each mouse were fixed in 10% (v/v) neutral buffered formalin for 24 h at 4°C. Tissue samples were embedded in paraffin and thin-sectioned (4 μm thickness). The sections were stained with hematoxylin and eosin (H&E) solution (Sigma-Aldrich, St. Louis, MO, USA) and mounted under cover slips using Dako-mounting medium (Dako Cytomation, Glostrup, Denmark). The stained sections were photographed using a photometric Quantix digital camera, and montages were assembled using Adobe Photoshop. To measure the degree of mast cell infiltration, the skin sections were stained with toluidine blue, and the numbers of mast cells were counted in four sites. The histological alternation of tissue was examined by two histopathologists.
Measurement of plasma IgE and histamine levels
Blood samples were drawn from the mice, separated by centrifugation at 10000 × g for 10 min at 4°C, and stored at -80°C. The levels of histamine (Oxford Biomedical Research, Oxford, MI, USA) and IgE (Bethyl Laboratories Inc., Montgomery, TX, USA) were measured in the plasma using ELISA kits, according to the manufacturer’s instructions.
All of in vitro experiments were performed at least three times. The dermatitis score was analyzed using Mann-Whitney’s U test. The concentration of IgE, histamine, PGE2, nitrite and TARC were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett’s test. The difference was considered significant at P < 0.05.
MAE inhibits nitrite and PGE2 production in LPS-stimulated RAW264.7 cells
MAE inhibits TARC production in TNF-α and IFN-γ stimulated HaCaT cells
MAE suppresses the severity of dermatitis and skin lesions in Biostir-AD-induced atopic dermatitis using NC/Nga mice
MAE attenuates the atopic dermatitis-like lesions induced by Biostir-AD
MAE inhibits the IgE and histamine levels in Biostir-AD-induced atopic dermatitis in NC/Nga mice
Atopic dermatitis is a chronic inflammatory skin disease, which is characterized by pruritic and eczematous skin lesions. Recently, atopic dermatitis has been increasing in industrialized countries, and it is a multifactorial disease with genetic and environmental components, such as infectious agents, food allergens, and aeroallergens. These environmental components elevate the serum IgE levels, which can be a strong trigger of infiltration by T cells, eosinophils, mast cells, macrophages, and keratinocytes .
Macrophages have a central role in the production of proinflammatory mediators during the inflammation response. Of the various proinflammatory mediators, nitrite and PGE2 have been found to be important in several physiological processes, including vasodilation, neurotransmission, blood coagulation, and immune regulation . NO is synthesized by inducible NO synthase (iNOS), while PGE2 is produced by cyclooxygenase 2 (COX-2) [20, 21]. They aggravate the inflammatory responses of atopic lesions, which are important feature is of atopic dermatitis . In our study, we found that MAE reduced NO and PGE2 production in a dose-dependent manner in LPS stimulated RAW 264.7 macrophage cells.
Keratinocytes produce chemokines and these factors are involved with the development of inflammatory skin diseases, such as atopic dermatitis . Chemokines can lead to a Th1/Th2 imbalance, which results in the development of atopic dermatitis lesions . The lymphocytes that are directed to the skin have recently been shown to express CC chemokine receptor 4, which is the receptor for the CC chemokine TARC. TARC is overexpressed by keratinocytes, especially in the epidermis of atopic dermatitis lesions in the murine model and atopic dermatitis patients . In this study, MAE inhibited TARC production in TI-stimulated HaCaT cells. Overall, these results suggest that MAE is effective in suppressing inflammatory responses and the development of atopic dermatitis by reducing TARC production.
NC/Nga mice have been used as an animal model of atopic dermatitis and share the clinical features of human atopic dermatitis . NC/Nga mice with atopic dermatitis exhibit various histopathological and pathophysiological changes compared with normal mice . The elevation of proinflammatory cytokines, IgE, and histamine are important features in the pathophysiology of NC/Nga mice with atopic dermatitis . Inflammatory cell infiltration, epidermis hypertrophy, intracellular edema, and hyperkeratosis are mainly observed in atopic dermatitis skin lesions . Our study also observed the characteristic pathophysiological alterations of atopic dermatitis. NC/Nga mice where atopic dermatitis was induced by house dust mites exhibited increased levels of IgE and histamine in their plasma compared with normal mice. They also exhibited epidermis hypertrophy, intracellular edema, and infiltration of inflammatory cells in their skin lesions. By contrast, MAE-treated NC/Nga mice had reduced histopathological changes in their skin lesions and lower plasma IgE and histamine levels. Based on these findings, a topical application of MAE may be effective for suppressing the atopic dermatitis induced by house dust mites.
Topical steroids, emollients, and oral anti-histamines are used as the first-line therapy for atopic dermatitis . Steroids are generally prescribed to control the symptoms of atopic dermatitis, but their repeated use can cause severe skin atrophy, susceptibility to infections, and other side effects. These profound side effects mean that chronic usage must be actively avoided. Thus, there is a strong need for the development of a herbal medicine that is effective for the treatment of atopic dermatitis, which should be safe and eco-friendly.
Our study demonstrated the inhibitory effects of MAE on atopic dermatitis. The inhibition of NO and PGE2 production was responsible for the anti-inflammatory effects of MAE, which may be associated with its inhibitory effect on TARC production by keratinocytes in dermatitis lesions. MAE also appeared to reduce the skin symptoms of atopic dermatitis, such as erythema, hemorrhage, and edema. The topical application of MAE significantly reduced the development of house dust mite-induced atopic dermatitis in NC/Nga mice. Overall, these findings provide scientific evidence that MAE has the potential to be developed as a therapeutic agent for the treatment of atopic dermatitis.
This work was supported by a grant from the Korea Institute of Oriental Medicine (No. K13030) and Korea Research Council of Fundamental Science & Technology (KRCF, No. G10101), Korea.
- Leung DY: Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol. 2000, 105: 860-876. 10.1067/mai.2000.106484.View ArticlePubMedGoogle Scholar
- Leung DY, Bieber T: Atopic dermatitis. Lancet. 2003, 361: 151-160. 10.1016/S0140-6736(03)12193-9.View ArticlePubMedGoogle Scholar
- Fujii Y, Takeuchi H, Sakuma S, Sengoku T, Takakura S: Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats. Skin Pharmacol Physiol. 2009, 22: 240-247. 10.1159/000235551.View ArticlePubMedGoogle Scholar
- Yang G, Lee K, Lee MH, Kim SH, Ham IH, Choi HY: Inhibitory effects of Chelidonium majus extract on atopic dermatitis-like skin lesions in NC/Nga mice. J Ethnopharmacol. 2011, 138: 398-403. 10.1016/j.jep.2011.09.028.View ArticlePubMedGoogle Scholar
- Shiohara T, Hayakawa J, Mizukawa Y: Animal models for atopic dermatitis: are they relevant to human disease?”. J Dermatol Sci. 2004, 36: 1-9. 10.1016/j.jdermsci.2004.02.013.View ArticlePubMedGoogle Scholar
- Yuksel H, Kirmaz C, Yilmaz O, Pinar E, Vatansever S, Degirmenci PB, Ozbilgin K: Nasal mucosal expression of nitric oxide synthases in patients with allergic rhinitis and its relation to asthma. Ann Allergy Asthma Immunol. 2008, 100: 12-16. 10.1016/S1081-1206(10)60398-5.View ArticlePubMedGoogle Scholar
- Bae KH: The medicinal plants of Korea. 2008, Seoul, Korea: Kyo-Hak Publishing Co., 73-Google Scholar
- Dugo P, Donato P, Cacciola F, Germano MP, Rapisarda A, Mondello L: Characterization of the polyphenolic fraction of Morus alba leaves extracts by HPLC coupled to a hybrid IT-TOF MS system. J Sep Sci. 2009, 32: 3627-3634. 10.1002/jssc.200900348.View ArticlePubMedGoogle Scholar
- Asano N, Yamashita T, Yasuda K, Ikeda K, Kizu H, Kameda Y: Polyhydroxylated alkaloids isolated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J Agric Food Chem. 2001, 49: 4208-4213. 10.1021/jf010567e.View ArticlePubMedGoogle Scholar
- Katsube T, Imawaka N, Kawano Y, Yamazaki Y, Shiwaku K, Yamane Y: Antioxidant flavonol glycosides in mulberry (Morus alba L.) leaves isolated based on LDL antioxidant activity. Food Chem. 2006, 97: 25-31. 10.1016/j.foodchem.2005.03.019.View ArticleGoogle Scholar
- Kikuchi T, Nihei M, Nagai H, Fukushi H, Tabata K, Suzuki T, Akihisa T: Albanol A from the root bark of Morus alba L. induces apoptotic cell death in HL60 human leukemia cell line. Chem Pharm Bull. 2010, 58: 568-571. 10.1248/cpb.58.568.View ArticlePubMedGoogle Scholar
- Choi EM, Hwang JK: Effects of Morus alba leaf extract on the production of nitric oxide prostaglandin E2 and cytokines in RAW2647 macrophages. Fitoterapia. 2005, 76: 608-613. 10.1016/j.fitote.2005.05.006.View ArticlePubMedGoogle Scholar
- Singab AN, El-Beshbishy HA, Yonekawa M, Nomura T, Fukai T: Hypoglycemic effect of Egyptian Morus alba root bark extract: effect on diabetes and lipid peroxidation of streptozotocin-induced diabetic rats. J Ethnopharmacol. 2005, 100: 333-338. 10.1016/j.jep.2005.03.013.View ArticlePubMedGoogle Scholar
- Arabshahi-Delouee S, Urooj A: Antioxidant properties of various solvent extracts of mulberry (Morus indica L.) leaves. Food Chem. 2007, 102: 1233-1240. 10.1016/j.foodchem.2006.07.013.View ArticleGoogle Scholar
- Ameen AM, Hapipah MA, Abdul AK, Mohd NS, Salmah I: Evaluation of the antiulcer activities of Morus alba extracts in experimentally induced gastric ulcer in rats. Biomed Res. 2009, 20: 35-39.Google Scholar
- Lee YJ, Choi DH, Kim EJ, Kim HY, Kwon TO, Kang DG, Lee HS: Hypotensive, hypolipidemic, and vascular protective effects of Morus alba L. in rats fed an atherogenic diet. Am J Chin Med. 2011, 39: 39-52. 10.1142/S0192415X11008634.View ArticlePubMedGoogle Scholar
- Lee JK, Ha H, Lee HY, Park SJ, Jeong SL, Shin HK: Inhibitory effects of heartwood extracts of broussonetia kazinoki sieb on the development of atopic dermatitis in NC/Nga mice. Biosci Biotechnol Biochem. 2010, 74: 1802-1806. 10.1271/bbb.100138.View ArticlePubMedGoogle Scholar
- Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M: The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001, 10: 11-18. 10.1034/j.1600-0625.2001.100102.x.View ArticlePubMedGoogle Scholar
- Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991, 43: 109-142.PubMedGoogle Scholar
- Mitchell JA, Larkin S, Williams TJ: Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol. 1995, 50: 1535-1542. 10.1016/0006-2952(95)00212-X.View ArticlePubMedGoogle Scholar
- Cookson W: The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol. 2004, 4: 978-988. 10.1038/nri1500.View ArticlePubMedGoogle Scholar
- Sandoval-López G, Teran LM: TARC: novel mediator of allergic inflammation. Clin Exp Allergy. 2001, 31: 1809-1812. 10.1046/j.1365-2222.2001.01268.x.View ArticlePubMedGoogle Scholar
- Hiramoto K, Kobayashi H, Ishii M, Sato E, Inoue M: Increased alpha-melanocyte-stimulating hormone (alpha-MSH) levels and melanocortin receptors expression associated with pigmentation in an NC/Nga mouse model of atopic dermatitis. Exp Dermatol. 2010, 19: 132-136. 10.1111/j.1600-0625.2009.00988.x.View ArticlePubMedGoogle Scholar
- Kim KC, Kim JS, Son JK, Kim IG: Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL‒60 cells by the Ganoderma lucidum and Duchesnea chrysantha extracts. Cancer Lett. 2007, 246: 210-217. 10.1016/j.canlet.2006.02.014.View ArticlePubMedGoogle Scholar
- Pokharel YR, Lim SC, Kim SC, Heo TH, Choi HK, Kang KW: Sopungyangjae-tang inhibits development of dermatitis in NC/Nga mice. Evid Based Complement Alternat Med. 2008, 5: 173-180.View ArticlePubMedGoogle Scholar
- Kobayashi H, Ishii M, Takeuchi S, Tanaka Y, Shintani T, Yamatodani A, Kusunoki T, Furue M: Efficacy and safety of a traditional herbal medicine, Hochu-ekki-to in the long-term management of kikyo (delicate constitution) patients with atopic dermatitis: A 6-month, multicenter, doubleblind, randomized, placebo-controlled study. Evidence-based Complementary and Alternative Medicine. 2010, 7: 367-373. 10.1093/ecam/nen003.View ArticlePubMedGoogle Scholar
- Berke R, Singh A, Guralnick M: Atopic dermatitis: an overview. Am Fam Physician. 2012, 86: 35-42.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/139/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.